- Home
- ASMB vs YSXT Comparison
ASMB vs YSXT Comparison
Compare ASMB & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- YSXT
- Stock Information
- Founded
- ASMB 2005
- YSXT 2011
- Country
- ASMB United States
- YSXT China
- Employees
- ASMB N/A
- YSXT N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- YSXT Automotive Aftermarket
- Sector
- ASMB Health Care
- YSXT Consumer Discretionary
- Exchange
- ASMB Nasdaq
- YSXT Nasdaq
- Market Cap
- ASMB 130.2M
- YSXT 127.7M
- IPO Year
- ASMB 2010
- YSXT 2024
- Fundamental
- Price
- ASMB $18.14
- YSXT $5.45
- Analyst Decision
- ASMB Strong Buy
- YSXT
- Analyst Count
- ASMB 3
- YSXT 0
- Target Price
- ASMB $33.00
- YSXT N/A
- AVG Volume (30 Days)
- ASMB 41.3K
- YSXT 371.8K
- Earning Date
- ASMB 08-07-2025
- YSXT 08-15-2025
- Dividend Yield
- ASMB N/A
- YSXT N/A
- EPS Growth
- ASMB N/A
- YSXT N/A
- EPS
- ASMB N/A
- YSXT 0.18
- Revenue
- ASMB $32,154,000.00
- YSXT $66,143,276.00
- Revenue This Year
- ASMB $0.04
- YSXT N/A
- Revenue Next Year
- ASMB N/A
- YSXT N/A
- P/E Ratio
- ASMB N/A
- YSXT $29.71
- Revenue Growth
- ASMB 148.33
- YSXT 21.23
- 52 Week Low
- ASMB $7.75
- YSXT $2.06
- 52 Week High
- ASMB $19.93
- YSXT $9.96
- Technical
- Relative Strength Index (RSI)
- ASMB 68.18
- YSXT N/A
- Support Level
- ASMB $17.45
- YSXT N/A
- Resistance Level
- ASMB $18.92
- YSXT N/A
- Average True Range (ATR)
- ASMB 0.87
- YSXT 0.00
- MACD
- ASMB -0.05
- YSXT 0.00
- Stochastic Oscillator
- ASMB 74.68
- YSXT 0.00
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.